← Back to Pipeline Dashboard Open Source Medicine Foundation

RSV vaccine (Pfizer Abrysvo)

Phase 2 Clinical Trial

Developer: Central Adelaide Local Health Network Incorporated  |  Target Disease: Vaccine Immune Response

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View Vaccine Immune Response Vaccine Guide →
Development Phase Phase 2 Clinical Trial Primary Status
Platform Technology Biological (unspecified platform) Biologic Architecture
Target Indication Vaccine Immune Response Pathogen / Antigen
Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Not Filed / Pre-submission
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture
Biological (unspecified platform)
Lead Developer
Central Adelaide Local Health Network Incorporated
Next Expected Milestone
Primary completion (most advanced trial): 2026-07 (registry estimate)
Analyst & Development Notes
Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation
ClinicalTrials.gov NCT07587801 →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT07587801 Phase 2 Clinical Trial

Vaccination Response Modulation With a Targeted Rapamycin Protocol Study

Status: Active / Ongoing • Expected Readout: 2026-07

Milestone Overview

  • Stage Verification
    Phase 2 Clinical Trial confirmed as of 2026-07-10.
  • Target Milestone
    Primary completion (most advanced trial): 2026-07 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.